NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…
Brain Biotech verkauft ihre Lizenzrechte an dem Wirkstoff-Projekt Deucrictibant an Royalty Pharma. Den Erlös beziffert die Gesellschaft auf bis zu…
BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für…
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general…
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general…
…
…
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has…
It is hard to get excited after looking at Royalty Pharmas (NASDAQ:RPRX) recent performance, when its stock has...…
Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain…
Earnings call: Royalty Pharma reports robust growth and strategic acquisitions…
…
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will…
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…
…
Earnings call: Royalty Pharma reports solid growth and portfolio expansion…
…
…
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…
…
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board…
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is…
Royalty Pharma ownership shows strong institutional and insider confidence…
Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop…
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to…
…
NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…
Royalty Pharma to pay $1 billion for Roches SMA drug royalties…
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with…
…
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of…
Royalty Pharma In $500 Million Royalty Pact for Gene Therapy Adstiladrin...…
NEW YORK and SAINT PREX, Switzerland, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and…
Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2023-08-10...…
Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2023-08-09...…
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the…
Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.41% and 1.20%, respectively, for the quarter ended June 2023. Do…
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings…
NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…
NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…
Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2023-07-12...…
Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2023-07-13...…
Legorreta, Pablo G. - Vorstand - Tag der Transaktion: 2023-06-28...…